Structure Therapeutics is trading 6.66% up now at $43.07 after September 8, 2026 clinical updates showed aleniglipron delivered up to 16.2% mean weight loss at 72 weeks, with no observed plateau.
- ACCG-2671 produced up to 3.3% weight loss after one dose.
- Rebound follows September 8's 14.70% decline as investors reassess the data and the company's competitiveness in oral obesity treatments.
- Broader market modestly lower; company-specific clinical news appears primary catalyst, with active September 9 morning trading.